Clarification for formulation of estropipate (Ogen)
Zinser, J.R.
American Family Physician 50(3): 542
1994
ISSN/ISBN: 0002-838X PMID: 8067323 Document Number: 428411
Document emailed within 1 workday
Related Documents
Bini, A.; Mesa-Tejada, R.; Fenoglio, J.J.; Kudryk, B.; Kaplan, K.L. 1989: Immunohistochemical characterization of fibrin(ogen)-related antigens in human tissues using monoclonal antibodies Laboratory Investigation; a Journal of Technical Methods and Pathology 60(6): 814-8212002: Tobramycin for nebulisation: new formulation. A high price for a small improvement in formulation Prescrire International 11(62): 177-178
2003: Sublingual selegiline: new formulation. New formulation: new risk of oral adverse effects Prescrire International 12(67): 179
Ponticelli, C.; Ruggeri, Z.M.; Gordon, Y.B.; Ardaillou, N.; Larrieu, M.J.; Tarantino, A.; Coppola, R.; Mannucci, P.M. 1979: Urinary excretion of factor-VIII-related antigen and fibrin(ogen) degradation fragments D and e after kidney transplantation Transplantation Proceedings 11(1): 448-451
Wang, Y.J.; Leesman, G.D.; Lipstein, M.E.; Basch, H.I.; Monkhouse, D.C. 1984: Optimization of autoclave cycles and selection of formulation for parenteral products, Part III: Effect of formulation variables on sporicidal kinetics Journal of parenteral science and technology: a publication of the Parenteral Drug Association 38(2): 78-82
Soni, S.D.; Tench, D.; Ashwood, T.J.; Movin, G. 1990: Pharmacokinetics of an oral controlled release formulation of remoxipride: a double-blind, crossover comparison with conventional formulation in chronic schizophrenics Acta Psychiatrica Scandinavica. Supplementum 358: 45-47
2003: Paracetamol for injection: new formulation. New formulation: why so widely used? Prescrire International 12(67): 178
Vens-Cappell, B.; Hilgenstock, C.; Gellert, M.; Kühle, K.; Reifferscheid, I.; Winckler, P.; Bührens, K.G. 1993: Comparison of the pharmacokinetics of a quick-release bezafibrate formulation with a sustained-release formulation. 1. Single-dose administration Arzneimittel-Forschung 43(3): 346-350
Jehl, F.; Klossek, J.M.; Peynegre, R.; Serrano, E.; Castillo, L.; Bobin, S.; Desprez, D.; Renault, C.; Neel, V.; Rouffiac, E.; Borie, C. 2002: Sinusal penetration of amoxicillin-clavulanic acid. Formulation 1 g./125 mg., twice daily versus formulation 500 mg./125 mg., three times daily Presse Medicale 31(34): 1596-1603
Scheidel, B.; Blume, H.; Walter, K.; von Nieciecki, A.; Babej-Dölle, R.M. 1993: Biological availability of gastric juice-resistant coated diclofenac preparations. 1. Bioavailability study following a single administration of a multiple-unit formulation in comparison with a single-unit formulation Arzneimittel-Forschung 43(11): 1211-1215
Bernstein, A.E. 1992: A point of clarification Journal of the American Medical Women's Association 47(5): 132 139
Haessler, G. 1990: Important clarification Iowa Medicine: Journal of the Iowa Medical Society 80(9): 431
Kurt, T.L. 1978: A clarification of numbers Circulation 57(5): 1031
Eriksson, C.P. 1994: Clarification of didanosine dosages Postgraduate Medicine 96(3): 26
Echeverry, Mía.Ladi.Londoño. 2004: Clarification from the Sí-Mujer Foundation Gaceta Medica de Mexico 140(2): 267; Author Reply 267-8
Baum, G.; Frey, M.; Santa Teresa, J. 1991: Clarification of ascites fluid Biotechniques 10(4): 456 458 460
Boyce, J.R. 1995: Clarification on firearms and ammunition Journal of the American Veterinary Medical Association 207(12): 1545
McCarthy, E.G.; Finkel, M.L. 1979: Necessary clarification of "unnecessary surgery" Surgery 85(6): 717
Beck, E.A. 1971: Diagnostic clarification of coagulopathies Schweizerische Medizinische Wochenschrift 101(46): 1653-1657
Unwin, D.H. 1993: Gamma knife article needs clarification Texas Medicine 89(8): 7-8